Mouse models

#Animal models #Animal testing #Mouse models #Non-animal model (NAM)

Considering the use of animal models in drug development

Professor Andy Whiting, CEO of Nevrargenics, asks whether animal models should be used as the default regulatory requirement and explores the times to use them. Animal models (AMs) have generally been seen as useful for drug development and biomedical research for many years. They are assumed to closely mimic human… Read More

#Exclusive Content

A laboratory mouse
#Clinical trials #Drug toxicity #In vivo #Mouse models #Preclinical development #Whitepaper

How can you ensure a confident transition to human trials?

A new whitepaper is now available from The Jackson Laboratory, entitled ‘Evidence-based selection of the starting dose in first-in-human clinical trials using humanised mouse models‘. This paper discusses the challenges drug developers face when transitioning from preclinical discovery to clinical trials and proposes expanding the drug development… Read More

#News

#Clinical trials #Drug toxicity #In vivo #Mouse models #Preclinical development

The in vivo tool enabling a confident transition to Phase I trials

This paper discusses the challenges drug developers face when transitioning from preclinical discovery to clinical trials and proposes expanding the drug development toolbox with humanised mouse models. Download the latest whitepaper to learn more about: The importance of selecting appropriate starting doses in clinical trials. Why humanised mice better predict… Read More

#Resources

Laboratory mouse
#Ageing #Antibody #Duke-NUS Medical School #Healthspan #Imperial College London #Medical Research Council Laboratory of Medical Science #Mouse models

Anti-IL-11 drug extends lifespan by over 20% in mice

Scientists have discovered that ‘switching off’ protein interleukin 11 (IL-11) can significantly increase the healthy lifespan of mice by almost 25%. The scientists at the Medical Research Council Laboratory of Medical Science (MRC LMS) and Imperial College London, working with colleagues at Duke-NUS Medical School in… Read More

#Editor's Choice #News

#Artificial intelligence (AI) #In vivo #Mouse models #Oncology #Oxford Drug Design

In vivo testing validates new approach to cancer treatment

In vivo testing has validated Oxford Drug Design’s potential first-in-class approach against multiple tumours, designed using its AI platform. The results of a 28-day mouse trial showed clear efficacy as well as dose response. The company’s approach is based on a novel target, leucyl-tRNA… Read More

#Cancer Research #News

Mouse in drug discovery research
#Animal models #Drug discovery #Genetically engineered models (GEMs) #Humanisation #Humanised Immune System (HIS) #Mouse models

Elevating drug discovery through access to in vivo models

This paid-for advertorial by Taconic Biosciences appeared in DDW Volume 25 – Issue 3, Summer 2024. Harnessing the power of sophisticated GEMs and humanized mice is essential to moving research forward. In the dynamic landscape of drug discovery, the utilisation of high-quality animal models is paramount for success. Among these models,… Read More

#Exclusive Content

Mouse in laboratory
#Bispecific therapeutics #Drug discovery #Human disease models #Mouse models #Preclinical development #Preclinical investigations #Toxicology

Case Study: Streamline preclinical drug discovery

A new Case Study is now available to download for free: ‘In Vivo Evaluation Of Bispecific-Cell Engager Efficacy & Safety‘. Discover a clinically predictive and reproducible platform developed by The Jackson Laboratory for simultaneous efficacy and safety assessment. This platform identifies patient-therapy combinations at risk of developing… Read More

#News

#Bispecific therapeutics #Drug discovery #Human disease models #Mouse models #Preclinical development #Preclinical investigations #Toxicology

Streamline preclinical drug discovery: PBMC-humanised mouse models

Discover a clinically predictive and reproducible platform developed by The Jackson Laboratory for simultaneous efficacy and safety assessment. This platform identifies patient-therapy combinations at risk of developing severe inflammatory syndrome, a potentially fatal complication. Optimise the safety profiles of your immunomodulatory therapeutics before first-in-human trials by leveraging this platform. In… Read More

#Resources

Bill & Melinda Gates Foundation
#Bill & Melinda Gates Foundation #Drug development #Drug discovery #Finance #Funding #Mouse models #PhaSER Biomedical (PhaSER)

$2.3m Gates Foundation grant to accelerate global drug discovery 

Edinburgh-based PhaSER Biomedical (PhaSER) has received a Bill & Melinda Gates Foundation grant totalling $2.3m to continue its work in accelerating drug discovery and development.   PhaSER will provide 8HUM transgenic mouse models, humanised for key pathways involved in the metabolism and disposition of drugs, to all the… Read More

#News

mRNA
#King's College London #Liver disease #Moderna #Mouse models #mRNA #Rare disease #University College London

Study reveals therapeutic potential of mRNA in rare diseases

Researchers have used messenger RNA (mRNA) to create an effective therapy for a rare liver disease in preclinical studies, demonstrating the technology’s potential therapeutic use in people. The team, led by University College London (UCL), King’s College London and Moderna scientists, found that mRNA could be… Read More

#Editor's Choice #News

MRI of the brain
#epilepsy #Gene therapy #Mouse models #Preclinical investigations #University College London

Gene therapy could reduce seizures in childhood epilepsy

University College London (UCL) researchers have developed a new gene therapy to cure focal cortical dysplasia, which a new study shows can significantly reduce seizures in mice. Focal cortical dysplasia is caused by areas of the brain that have developed abnormally and is among the most… Read More

#Editor's Choice #News

Antibodies
#Guide #Human disease models #Mouse models #Pharmokinetics #Therapeutic Antibodies

Guide: Assessing preclinical PK in therapeutic antibodies

A new Guide is now available from The Jackson Laboratory (JAX) entitled ‘HuPK: A Humanised Platform for therapeutic antibody PK evaluation’. Download the Guide to learn more about:   How JAX’s HuPK™ Humanised FcRn Platform offers a validated and… Read More

#News

#Drug development #Drug discovery #Guide #Human disease models #Mouse models #Pharmokinetics

HuPK: A Humanised Platform for therapeutic antibody PK evaluation

Download the guide to learn more about:   How JAX’s HuPK™ Humanised FcRn Platform offers a validated and cost-effective solution for assessing the in vivo  preclinical pharmacokinetics and stability of Fc-based biologics and therapeutics carried by albumin.    JAX’s… Read More

#Intelligence #Resources

AAV virus
#Cell and gene therapy #Mouse models

How to advance AAV-based gene therapies

Sara Donnelly, Director of Research Planning and Business Development at PhoenixBio USA explores why the right pre-clinical model is essential for teams wanting to advance adeno-associated virus vector-based gene therapies.   Adeno-associated virus (AAV) vector-based gene therapies hold exceptional promise across a range of disease areas. We’re beginning to see their… Read More

#Exclusive Content

Human brain
#Depression #Genetics / genomics #Korea #Major depressive disorder #Mouse models #Neuroscience

Researchers uncover molecular pathways underlying depression

Scientists have discovered the link between gene expression, DNA methylation, and brain structural changes in depression, revealing new potential therapeutic targets. By analysing gene interactions in mice subjected to behavioural tests, the researchers from Korea University Anam Hospital, Konkuk University, and Sahmyook University identified 141 genes… Read More

#News

#Clinical trials #Humanisation #IBD #Mouse models

How humanized mouse models can improve outcomes for IBD

Kiave Yune Ho Wang Yin, PhD, Chief Business Officer at TransCure bioServices explores how humanized mouse models can be used to develop more relevant preclinical studies for IBD treatments and ultimately increase the likelihood of a treatment's success in clinical trials.  Inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis… Read More

#Exclusive Content